Connect with us

Latest News

Oral Syringes Market Size Worth $868.6 Million by 2027 | CAGR: 4.2%: Grand View Research, Inc.

Vlad Poptamas

Published

on

 

The global oral syringes market size is expected to reach USD 868.6 million by 2027, expanding at a CAGR of 4.2%, according to a new report by Grand View Research, Inc. The ability to deliver an accurate amount of medication, increase in the pediatric and geriatric surgeries, and the easy usability of the oral syringes are expected to propel market growth over the forecast period. In addition, recent development in the design and increase in the demand are expected to contribute to market growth.

Medication errors in the pediatric population are also expected to drive the market. According to the article published in the U.S. Pharmacist in 2019, approximately 200,000 medication errors are reported to the U.S. poison control centers every year and about 30.0% of cases are related to children. Unlike most drugs for adults, children’s medications are often liquid and administration of liquid medication by cups and spoons leads to serious errors. To reduce the incidence of medication errors in children, most of the healthcare agencies are promoting the use of the dispensers worldwide. For instance, the Institute for Safe Use of Medications (ISMP) publishes periodical newsletters and educational programs to increase the awareness regarding the dispenser in Spain.

Key suggestions from the report:

  • By type, the clear oral syringes segment held the largest market share in 2019 owing to the low price in the industry
  • Reusable oral syringes held the largest market share of 51.0% in 2019 owing to their affordability and ability to pre-sterilize
  • The hospital segment held the largest market share due to the increase in the number of hospitalization throughout the world
  • Asia Pacific is expected to witness the fastest growth rate over the forecast period owing to a large number of pediatric population and increase in the awareness in the region.

Read 90 page research report with ToC on “Oral Syringes Market Size, Share & Trends Analysis Report By Product Type (Clear, Colorful), By Usage (Disposable, Reusable), By End Use (Hospitals, Clinics), By Region, And Segment Forecasts, 2020 – 2027” at: https://www.grandviewresearch.com/industry-analysis/oral-syringes-market

In addition, rise in the birth rate across the world, minimum regulation for the consumable devices, and easy usability of the dispenser are expected to drive the market over the forecast period. Furthermore, benefits such as high reliability and dose accuracy over cups or droppers are increasing demand for the dispensers in the industry. According to survey conducted by the National Center for Biotechnology Information, most of the children’s hospitals and residency hospitals use oral syringes in U.S.

North America accounted for the highest market share in 2019 owing to advanced healthcare system and growing prevalence of chronic diseases in the country. In addition, the presence of major players in the region contributed to market growth.

Grand View Research has segmented the global oral syringes market based on product type, usage, end use, and region:

  • Oral Syringes Product Type Outlook (Revenue, USD Million, 2016 – 2027)
    • Colorful
    • Clear
  • Oral Syringes Usage Outlook (Revenue, USD Million, 2016 – 2027)
    • Disposable
    • Reusable
  • Oral Syringes End-use Outlook (Revenue, USD Million, 2016 – 2027)
    • Hospitals
    • Clinics
    • Homecare Settings
  • Oral Syringes Regional Outlook (Revenue, USD Million, 2016 – 2027)
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Spain
      • Italy
      • Netherlands
      • Belgium
      • Switzerland
      • Russia
      • Sweden
    • Asia Pacific
      • India
      • Japan
      • China
      • Australia
      • South Korea
      • Malaysia
      • Indonesia
      • Singapore
      • Philippines
      • Thailand
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
      • Chile
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Egypt
  • List of Key Players in Oral Syringes Market:
    • Becton
    • Dickinson and Company
    • Braun Melsungen AG
    • Medtronic
    • Amcor Limited
    • Smiths Medical
    • NIPRO Corporation
    • Gerresheimer AG
    • Terumo Corporation

Find more research reports on Medical Devices Industry, by Grand View Research:

  • Urology Laser MarketRising preference for minimally-invasive surgeries, and technological advancements are some of the factors driving the market growth.
  • Dental Fillings Markethigh prevalence of other dental conditions, such as tooth decay and cavity due to unhealthy eating habits along with increasing patient awareness and growing geriatric population are expected to fuel the market.
  • Transcatheter Devices Marketgrowing preference for transcatheter replacement or repair procedures over open heart surgery are the key factors contributing to the market growth.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

Artificial Intelligence

Real estate, re-imagined: Lone Wolf introduces new cloud solutions for agents, brokers, teams, franchises, MLSs, and associations

Vlad Poptamas

Published

on

 

Lone Wolf Technologies (“Lone Wolf”) is thrilled to announce the availability of real estate’s first integrated suites of technology solutions targeted to the specific and unique needs of residential real estate stakeholders: Agent Cloud, Team Cloud, Broker Cloud, Franchise Cloud, and Organization Cloud. Each cloud solution connects real estate’s leading technology in a single package and is available for purchase today through lwolf.com.

“We’re excited to announce the release of our cloud solutions today,” said Jimmy Kelly, CEO of Lone Wolf. “The industry has long sought end-to-end solutions, but no one’s been able to make it happen. We’ve done that, and more. By fully integrating our solutions and connecting them to some of the best tech providers in North America, we’ve not only delivered an end-to-end solution, but an entire suite of end-to-end solutions tailored to each stakeholder role in the industry. And we’re doing it with the best tech available today, from forms, eSignature, and transaction management to back office, accounting, and insights. With Lone Wolf’s clouds, it’s now possible to have a complete—and completely connected—digital experience, whether you’re an agent, broker, administrator, or buyer and seller. That’s real estate re-imagined.”

The Broker Cloud features a collection of real estate’s leading digital solutions to give brokers everything they need to run their business, serve their buyers and sellers, and improve profitability. Solutions include:

  • Lone Wolf Transactions, formerly known as zipForm Plus and TransactionDesk, the broker add-on to the national member benefits in both the U.S. and Canada. Transactions provides 99% forms coverage in North America, real estate’s number-one eSignature solution, and a two-way integration between agents and the back office to give the whole brokerage unrivaled transaction management capabilities.
  • Lone Wolf Back Office, formerly known as brokerWOLF, the back office and accounting solution used by over 10,000 offices in North America. The solution seamlessly connects to Transactions and features the industry’s most comprehensive tools for agent management, accounting, commissions, and business intelligence, giving brokerages of any make and model everything they need to run their business.
  • Lone Wolf Insights, an AI-enabled solution that translates Back Office data into plain language and puts profitability in the broker’s hands, providing them with actionable insights to improve agent performance and bolster their coaching and retainment efforts.
  • Lone Wolf Marketplace, a curated library of best-in-class digital tools that plug and play so that agents and brokerages can manage their client experience from start to finish in one solution.

“What makes our clouds truly special is they’re built around the transaction itself,” said Graeme Canivet, Product Director of Transactions at Lone Wolf. “A transaction is the moment of truth that connects everyone—and everything—in real estate. It’s where agents, brokers, staff, buyers and sellers, and third-party providers like title companies come together with a common goal. Our cloud solutions bring together the various people and technologies involved in a transaction, making it simpler for all.”

The Agent Cloud is a complete suite of solutions that connects every aspect of an agent’s transactions to provide an unrivaled client experience, including:

  • Lone Wolf Transactions, which powers the national member benefits in Canada and the U.S., as well as hundreds of local and state associations, to provide agents with instant MLS connectivity and the industry’s most up-to-date and legally binding forms.
  • Authentisign, real estate’s leading eSignature tool, which processes over 22 million signatures a year and is built right into Transactions, so agents do not have to export contracts to a third-party signing solution.
  • Lone Wolf Marketplace, a curated library of best-in-class digital tools that plug and play into Transactions, so agents can manage the entire deal and client experience in a single place.
  • Lone Wolf EliteAgent, which provides additional digital tools to help drive agent productivity, including offer management, listing broadcast, mobile add-ons and more.

“One of the biggest obstacles real estate has in providing a complete digital experience is the adoption of new tech,” said Matt Keenan, Chief Revenue Officer at Lone Wolf. “The acquisition of zipLogix and Instanet Solutions allowed Lone Wolf to build a best-in-class suite of solutions that is tightly integrated with MLSs and associations across North America, so agent adoption is already built in. With our cloud solutions, we believe it’s finally possible for all participants in the real estate industry to have an unparalleled digital real estate experience.”

Continue Reading

Artificial Intelligence

AI Predicts Newborn Chronic Lung Disease in Breakthrough Clinical Study

Vlad Poptamas

Published

on

 

SIME, an early stage Clinical AI company specialising in data driven and rapid ICU diagnostics, has completed a breakthrough clinical study validating the world’s first predictive test for neonatal Chronic Lung Disease (CLD), a major cause of morbidity and mortality in premature babies. The preliminary multicentre study, entitled “Bronchopulmonary dysplasia predicted at birth by artificial intelligence“, was published in Acta Paediatrica, a peer-reviewed journal [DOI: 10.1111/apa.15438].

This innovative digital test is set to revolutionise respiratory medicine in the Neonatal Intensive Care Unit (NICU). By screening for CLD at birth, clinicians will be able to deliver early targeted treatment before disease onset; enabling them to improve clinical outcomes, prevent chronic comorbidities and reduce costs.

First described more than 50 years ago, CLD (i.e. Bronchopulmonary Dysplasia/BPD) remains one of the most serious challenges in the care of preterm babies. Affecting approximately one-quarter of babies with a birth weight below 1,500 g, CLD is associated with prolonged NICU hospitalisation, greater risk of mortality and lifelong medical and neurodevelopmental disorders. Although there is a large acute unmet need, there is currently no predictive test available for CLD. Today, diagnosis is only confirmed when a baby still requires oxygen and assisted ventilation 28 days after birth.

CLD has always been one of the most poorly understood and most complex conditions to treat in neonatology. A critical problem made even more challenging by the lack of a diagnostic and, consequently, late and sub-optimal treatment. A rapid screening test at birth will enable doctors to treat early and preventatively, improving outcomes and reducing time in intensive care,” explained Prof. Henrik Verder, Department of Paediatrics, Holbaek University Hospital in Denmark and lead author of the paper. “Furthermore, a lack of knowledge about the mechanisms of CLD has historically hindered the development of new therapeutics. We believe that the novel data and insights generated by this study could hold the key to treatment innovation.”    

SIME’s Clinical AI platform was used to analyse proprietary datasets generated during a previous clinical trial of the company’s first diagnostic application: a newborn lung maturity test for Respiratory Distress Syndrome (RDS)1. To conduct the analysis, SIME merged 2 unique datasets from premature babies: digitized biological data and clinical data. This innovative combination of multivariate data aggregation and AI analysis, enabled the study partners to rapidly develop a predictive CLD test in less than 2 months. The test was shown to predict CLD with high accuracy (sensitivity of 88% and a specificity of 91%) in 61 preterm babies (gestational age 24-31 weeks). Additional clinical studies to further validate the test are currently underway.

The CLD test will be the second application on the company’s Clinical AI Platform, offering NICU clinicians a combined rapid screening tool for the two most severe and life-threatening respiratory diseases in neonatology. Predictive diagnosis of both CLD and RDS at birth, has the potential to change the standard of respiratory care for millions of babies worldwide.

Continue Reading

Artificial Intelligence

How Russian Steelmakers Could Capitalise in a Post COVID-19 World

Vlad Poptamas

Published

on

 

Russia is among the biggest steel exporters in the world, delivering to a wide range of destinations. However, steel demand in all regions diminished as the world was hit by COVID-19 and most steel producers globally have struggled. Unlike steelmakers in other regions, Russian producers did not idle capacity but extended maintenances and lowered capacity utilisation in order to reduce output. Going forward, however, they will have to decide whether to take more decisive measures to keep production restricted, dependant on their ability to leverage their cost competitive advantages and the growth opportunities that export markets present.

Given that domestic steel demand is expected to remain weak in 2020, we believe that Russian mills will increase exports due to their low-cost advantages. There will be stronger exports to the EU, with expanded quota volumes, and to Southeast Asia, where demand is expected to recover faster than in other regions. This will not be enough, however, to sustain 2019 output levels and production in Russia will decline by 8% y/y.

Even during 2021, Russian demand is not expected to recover to pre-pandemic levels and output will be dependent on export demand. There is a risk of lower exports to the EU ultimately, due to the possible introduction of carbon border tariffs that could, feasibly, be introduced during the year. Sales to Southeast Asia, however, will be strong as demand there will be rising fast. As a result, net exports will rise and steel production will return to pre-COVID-19 levels by end-2021.

A strong domestic market premium reduced Russian steel exports in 2019

In 2019, carbon steel exports from Russia reduced by 12% y/y, to 27 Mt, as sales to traditional markets, such as Turkey, North America and the EU, fell sharply. On the other hand, exports to Asia rose by 9%, with Taiwan remaining the main destination and receiving over 3.5 Mt of material.

Total exports were lower for a few reasons. Firstly, domestic demand for finished steel products in Russia increased by almost 10% during the year, while crude steel production remained virtually unchanged due to an already high capacity utilisation. This pulled the domestic market premium higher—for rebar it was $55 /t in 2019 compared with just $5 /t in 2018 and, for HR coil, the premium was $107 /t in 2019 compared with $55 /t a year earlier. With high premiums, producers naturally diverted more material to the domestic market to maximise profits.

Continue Reading

Trending

Roboticulized is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Roboticulized digests / hand picks the latest news about the AI industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Roboticulized.com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania